Establishing a new screening system for mild cognitive impairment and Alzheimer’s disease with mental rotation tasks that evaluate visuospatial function

Manuscript Number: 

17-0801R1

Author(s): 
Noriyuki Matsukawa, Takashi Nagamine, Shun Shimohama, Jun Shinozaki, Ayuko Suzuki, Yoshino Ueki, Shogo Yazawa

Disclosures

Noriyuki Matsukawa

  • Nothing to Disclose

Takashi Nagamine

  • Lecture Fees:
    Speaking fees at two commercially-sponsored meetings from Otsuka Pharmaceutical Co. Ltd.

Shun Shimohama

  • Lecture Fees:
    Novartis Pharma Co., Boehringer Ingelheim Co., Kyowa Hakko Kirin Co., Dainippon Sumitomo Pharma Co., Takeda Pharmaceutical Co., Daiichisankyo Pharma Co., Jansen Pharma Co., Eisai Pharma Co.,Biogen Idec Co., Mitsubishi Tanabe Pharma Co.. Otsuka Pharmaceutical Co.
    Grants
    • Agency: 
      Novartis Pharma Co., Kyowa Hakko Kirin Co., Dainippon Sumitomo Pharma Co., Takeda Pharmaceutical Co., Daiichisankyo Pharma Co., Jansen Pharma Co., Eisai Pharma Co.,
      Dates: 
      2017

Jun Shinozaki

  • Nothing to Disclose

Ayuko Suzuki

  • Nothing to Disclose

Yoshino Ueki

  • Nothing to Disclose

Shogo Yazawa

  • Nothing to Disclose